The short version of clinical development fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
== Powers and abilities == Major Force is coated with the same Dilustel alien alloy that covers Captain Atom. As a result, he also can access the Quantum Field and use its energies for a variety of powers. Cracking or rupturing his Dilustel skin causes Major Force to leak radiation at an uncontrollable rate, to which he runs the risk of atomic detonation. Major Force can project blasts of dark matter and shape the energy into various forms. He initially lacked the ability to fly, but rather leapt great distances or traveled on ramps made of dark matter. Major Force is also able to convert whatever force he comes in contact with, be it matter or energy, into solid dark matter. Major Force possesses immense strength and durability, around the same level as Captain Atom and Superman. Major Force lacks the need for physical sustenance thanks to the Dilustel's connection to the Q-Field, allowing to survive indefinitely without need to eat, sleep, breath or rest, and survive in the vacuum of space. Due to his nature as pure energy, Major Force is functionally immortal. Clifford Zmeck is a military-trained United States Air Force operative. He has vast military connections with the government, Checkmate, Task Force X, and Quorum.
Recent studies found a clear association between long-term oral (or intravenous) anticoagulant treatment (OAC) and reduced bone quality due to reduction of active osteocalcin. OAC might lead to an increased incidence of fractures, reduced bone mineral density or content, osteopenia, and increased serum levels of undercarboxylated osteocalcin. Furthermore, OAC is often linked to undesired soft-tissue calcification in both children and adults. This process has been shown to be dependent upon the action of K vitamins. Vitamin K deficiency results in undercarboxylation of MGP. Also in humans on OAC treatment, two-fold more arterial calcification was found as compared to patients not receiving vitamin K antagonists. Among consequences of anticoagulant treatment: increased aortic wall stiffness, coronary insufficiency, ischemia, and even heart failure. Arterial calcification might also contribute to systolic hypertension and ventricular hypertrophy. Anticoagulant therapy is usually instituted to avoid life-threatening diseases, and high vitamin K intake interferes with anticoagulant effects. Patients on warfarin (Coumadin) or being treated with other vitamin K antagonists are therefore advised not to consume diets rich in K vitamins.
==== Honorary appointments ==== Honorary General of the Swedish Army, 1888 Colonel-in-chief of the 1st King's Dragoon Guards, British Army, 25 March 1896 – 1914 Colonel-in-chief of the Kexholm Life Guards Grenadier Regiment, Russian Army, until 26 June 1914 Colonel-in-chief of the 12th Belgorod Lancer Regiment, Russian Army, until 26 June 1914 Colonel-in-chief of the 16th (Schleswig-Holstein) Hussars, German Army Colonel-in-chief of the 122nd (Emperor Francis Joseph of Austria, King of Hungary (4th Württemberg) Fusiliers Honorary Colonel of the 38th León Infantry Regiment, Spanish Army, 30 November 1905 Field Marshal of the British Army, 1 September 1903 – 1914
Sources: en.wikipedia.org
The group released several reports on these effects as a cover story, claiming that their ionospheric studies had been interfering with the other experiments at the RRS at Slough, and expressing their gratitude that the Air Ministry had granted them access to unused land at Orfordness to continue their efforts. Bowen continued increasing the voltage in the transmitter, starting with the 5000 volt maximum suggested by the Navy, but increasing in steps over several months to 12,000 V, which produced pulses of 200 kW. Arcing between the valves required the transmitter to be rebuilt with more room between them, while arcing on the antenna was solved by hanging copper balls from the dipole to reduce corona discharge. By June the system was working well, although Bainbridge-Bell proved to be so skeptical of success that Watt eventually returned him to the RRS and replaced him with Nick Carter. The Tizard Committee visited the site on 15 June to examine the team's progress. Watt secretly arranged for a Vickers Valentia to fly nearby, and years later insisted that he saw the echoes on the display, but no one else recalls seeing these. Watt decided not to return to the RRS with the rest of the Tizard group and stayed with the team for another day. With no changes made to the equipment, on 17 June the system was turned on and immediately provided returns from an object at 17 mi (27 km). After tracking it for some time, they watched it fly off to the south and disappear.
== Further reading == Reineccius, Gary (1998). Sourcebook of Flavors. Berlin: Springer. ISBN 978-0-8342-1307-4. Fennema, O.R., ed. (1985). Food Chemistry (2nd ed.). New York: Marcell Dekker, Inc. pp. 46–50. Bell, L.N.; Labuza, T.P. (2000). Practical Aspects of Moisture Sorption Isotherm Measurement and Use (2nd ed.). Egan, MN: AACC Egan Press.
== Early life and education == Delibegovic is from Tuzla in Bosnia and Herzegovina. She grew up during the Bosnian War, which forced her family apart. In the early nineties, she moved to Scotland and finished her secondary school education at George Heriot's School in Edinburgh. Delibegovic studied pharmacology at the University of Edinburgh. In the final year of her undergraduate degree Delibegovic moved to Essex, where she did her undergraduate final year project at GlaxoSmithKline on novel anti-diabetes drugs. She completed her doctoral research with Prof Dame Patricia Cohen at the University of Dundee Medical Research Council Protein Phosphorylation Unit. Here she studied the way that enzymes such as protein phosphatase 1 influenced diabetes development. She was supported by the Royal Society studentship. She has said that she was interested in diabetes because of family history and prevalence of Type 2 diabetes in Bosnia and Herzegovina. During her doctoral research, Delibegovic worked closely with pharmaceutical companies to translate her research to the read world. In 2003 she was awarded the American Heart Association personal fellowship to study the role of PTPN1 in glucose homeostasis at the Harvard Medical School in Boston, USA. She spent four years in Boston, working with Prof Benjamin Neel on mouse models of insulin resistance.
===== Southern Land Bridge project ===== Paetongtarn Shinawatra has adopted the 1-trillion-baht Southern Land Bridge project as a cornerstone of her administration's economic policy, positioning herself as its chief advocate and lead promoter on the international stage. Her role is multifaceted, encompassing policy direction, investment promotion, and stakeholder management for one of Thailand's most ambitious and controversial mega-projects. The project aims to construct a 90-kilometer logistics corridor, including deep-sea ports in Ranong (Andaman Sea) and Chumphon (Gulf of Thailand), linked by a motorway and dual-track railway. This would create a strategic alternative to the congested Strait of Malacca for maritime transport. She has argued that it will reduce shipping times by several days, lower costs by up to 15%, create an estimated 280,000 jobs, and boost GDP growth. During numerous overseas roadshows and at major domestic events like the "Ignite Thailand" forum in March 2025, she has presented the project as a key opportunity for investment. She has actively courted interest from global players, particularly during her official visit to China in February 2025, and has highlighted investment interest from firms in China, the Middle East (notably Dubai Port World), and financial institutions like the Asian Infrastructure Investment Bank (AIIB).
Sources: en.wikipedia.org
=== Soundtrack === The soundtrack for The Orange Box consists of music that Valve employees composed for Half-Life 2: Episode One, Half-Life 2: Episode Two, Portal, and Team Fortress 2. It also includes the original version and an exclusive remix of "Still Alive", both by Jonathan Coulton. It was released on December 21, 2007, and is sold by the official Valve Store, Amazon.com, and digital music services such as iTunes, Napster, and eMusic. A more-complete version of this soundtrack that also includes music files from Half-Life and Half-Life 2 was released on Steam as part of the Audiosurf package. "Still Alive" was subsequently released as a free downloadable song for the rhythm game Rock Band on March 31, 2008.
== Medical importance == Mammalian stanniocalcins are known to be related to cancer development, such as breast and ovarian cancers. In these cancers, both STC1 and STC2 are excessively produced. Their location in chromosomes are the sites of genes for tumour formation. In breast cancer the elevated hormones correspond to increased estrogen receptors. Increased STC1 is specifically linked to other cancer types, including leukemia, colorectal cancer, carcinoma, and lung cancer. STC2 is related to cervical cancer, and ovarian cancer.
Jürgen Sundermann (28 May 1991 – 30 June 1993) Bernd Stange (1 July 1993 – 21 February 1994) Jürgen Sundermann (22 February 1994 – 8 April 1994) Damian Halata (9 April 1994 – 30 June 1994) Tony Woodcock (1 July 1994 – 30 October 1994) August "Gustl" Starek (31 October 1994 – 30 May 1996) Damian Halata (1 June 1996 – 30 June 1996) Sigfried "Siggi" Held (1 July 1996 – 7 October 1997) Damian Halata (8 October 1997 – 30 June 1998) Hans-Ulrich "Uli" Thomale (1 July 1998 – 28 March 1999) Dragoslav Stepanović (29 March 1999 – 29 August 1999) Joachim Steffens (30 August 1999 – 22 July 2001) Hans-Jürgen "Dixie" Dörner (23 July 2001 – 26 March 2003) Detlef Schößler (27 March 2003 – 3 June 2003) Hermann Andreev (24 June 2003 – 19 March 2004) Michael Breitkopf and Jörg Engelmann (20 March 2004 – 22 April 2004) Mike Sadlo (23 April 2004 – 30 June 2004) – Player/manager 1. FC Lok Leipzig
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.